Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Non-cash Items (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Non-cash Items for 5 consecutive years, with $48000.0 as the latest value for Q4 2025.

  • Quarterly Non-cash Items changed N/A to $48000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $48000.0 for FY2025, N/A changed from the prior year.
  • Non-cash Items for Q4 2025 was $48000.0 at Actinium Pharmaceuticals, up from $1000.0 in the prior quarter.
  • The five-year high for Non-cash Items was $12.5 million in Q1 2024, with the low at $152.0 in Q1 2025.
  • Average Non-cash Items over 5 years is $1.6 million, with a median of $48000.0 recorded in 2025.
  • The sharpest move saw Non-cash Items skyrocketed 627150.0% in 2024, then crashed 100.0% in 2025.
  • Over 5 years, Non-cash Items stood at $276000.0 in 2021, then plummeted by 98.19% to $5000.0 in 2022, then surged by 7360.0% to $373000.0 in 2023, then tumbled by 99.35% to $2409.0 in 2024, then soared by 1892.53% to $48000.0 in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $48000.0, $1000.0, and $300000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.